

Table of Contents

VOLUME 1

Section 1.0: FDA Executive Summary

Section 2.0: FDA Questions

Section 3.0: PMA Voting Options

Section 4.0: Sponsor Executive Summary

Section 5.0: XIENCE V Everolimus-Eluting Coronary Stent System Description

Section 6.0: XIENCE V EECSS Clinical Experience – Individual Trial Summaries

6.1 SPIRIT FIRST

6.2 SPIRIT II

6.3 SPIRIT III RCT

6.4 SPIRIT III 4.0 mm

6.5 Clinical Pharmacology

6.6 Overall Conclusions

Section 7.0: XIENCE V EECSS Proposed Post Approval Study

7.1 SPIRIT IV

7.2 XIENCE V USA

Attachment 7A XIENCE V USA Post-Approval Protocol

Section 8.0: XIENCE V EECSS Summary of Safety and Effectiveness

Section 9.0: Labeling

9.1 Instructions for Use

9.2 Patient Labeling

Attachment 9A XIENCE V EECSS Instructions for Use

Attachment 9B Patient Information Guide

Section 10.0: References

VOLUME 2

Appendix 1: SPIRIT FIRST Reports

Appendix 2: SPIRIT II Reports

CONFIDENTIAL

May not be reproduced without written permission from Abbott Vascular.

VOLUME 3

Appendix 3: SPIRIT III RCT Reports

VOLUME 4

Appendix 4: SPIRIT III 4.0 mm Reports

CONFIDENTIAL

May not be reproduced without written permission from Abbott Vascular.